Subacute Cutaneous Lupus Erythematosus

  • M. N. Manoussakis
  • H. M. Moutsopoulos


Subacute cutaneous lupus erythematosus (SCLE) represents a relatively distinct and homogeneous subset of lupus erythematosus (LE). It is identified by chronic and recurrent development of characteristic erythematous, nonscarring and mostly photosensitive skin lesions, associated with particular clinical, immunological and genetic features. SCLE-specific cutaneous lesions include the papulosquamous-psoriasiform eruption and the annular-polycyclic erythema. They are found in approximately 10% of total LE patients and affect predominantly white women of all ages. In addition, a significant proportion of patients with SCLE eruptions may have Sjogren’s syndrome (SS). Extracutaneous manifestations are usually, but not always, mild. Serum autoantibodies to RoSS-A cellular antigen that occur in approximately 25%–30% of total systemic lupus erythematosus (SLE) patients, are more common in SCLE (found in 60%–70%) suggesting that SCLE comprises roughly 30%–40% of all antiRoSS-A positive patients. Approximately 50% of antiRoSS-A positive SCLE patients display also serum antiLaSS-B antibodies. Associations of SCLE with HLA-DR3, HLA-DR2 as well as C4 null alleles have also been reported. Finally, besides SLE and SS, a number of other systemic diseases that have been described to precede, to coincide with or to follow the onset of SCLE include rheumatoid arthritis, porphyria cutanea tarda, Sweet’s syndrome, malabsorption, gluten-sensitive enteropathy, hereditary angioedema and various malignancies, including malignant melanoma, lung, breast and gastric cancer.


Systemic Lupus Erythematosus Cutaneous Lupus Erythematosus Hereditary Angioedema Porphyria Cutanea Tarda Clobetasol Propionate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sontheimer RD, Provost TT (1997) Cutaneous manifestations of Lupus Erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ Lupus Erythematosus. Williams and Wilkins, Baltimore, Maryland, pp 569–623Google Scholar
  2. 2.
    Duna GF, Cash JM (1995) Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 21: 99–115Google Scholar
  3. 3.
    Furner BB (1990) Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 29: 542–547PubMedCrossRefGoogle Scholar
  4. 4.
    Fenton DA, Black MM (1986) Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 11: 102–103PubMedCrossRefGoogle Scholar
  5. 5.
    Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H (1992) Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 127: 513–518PubMedCrossRefGoogle Scholar
  6. 6.
    Naafs B, Bakkers EJM, Flinterman J, Faber WR (1982) Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 107: 83–86PubMedCrossRefGoogle Scholar
  7. 7.
    Drosos AA, Dimou GS, Siamopoulou-Mavridou A, Hatzis J,Moutsopoulos HM (1990) Subacute cutaneous lupus erythematosus in Greece. A clinical, serological and genetic study. Ann Med Interne 141: 421–414Google Scholar
  8. 8.
    Manoussakis MN, Moutsopoulos HM (1996) Antimalarials in Sjogren’s syndrome–the Greek experience. Lupus 5 [Suppl 11: 28–30CrossRefGoogle Scholar
  9. 9.
    Wallace DJ (1997) Occasional, Innovative and Experimental Therapies. In: Wallace DJ, Hahn BH (eds) Dubois’ Lupus Erythematosus. Williams and Wilkins, Baltimore, Maryland, pp 1191–1202Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • M. N. Manoussakis
  • H. M. Moutsopoulos

There are no affiliations available

Personalised recommendations